What is patellar tendinopathy and who gets it

Anterior knee pain that flares with activity but settles at rest deserves careful attention — not because it is always serious, but because the tendon structure at its centre can deteriorate silently if the cause is not addressed.

Patellar tendinopathy — commonly called jumper's knee — is an overuse injury of the patellar tendon, the cord of connective tissue that runs from the kneecap (patella) down to the bony prominence at the top of the shin (the tibial tuberosity). This tendon transmits the full force of the quadriceps muscles every time the knee straightens, and repeated high-load cycles — most often from jumping or running sports — can produce cumulative microtrauma that outpaces the tendon's capacity to repair itself.

Pain is centred almost exclusively at the inferior pole of the patella, the lower tip of the kneecap where the tendon originates. That specific attachment point is the enthesis, and pathology confined to it is termed patellar enthesopathy. When the process is driven by inflammation, the more precise term is enthesitis — a distinction that carries real management implications, since inflammatory enthesopathy may respond to different interventions than purely degenerative disease. Mid-substance tendon disease, further along the tendon body rather than at the bony insertion, can coexist with insertional pathology but often follows a distinct course.

The characteristic symptom pattern — pain with load, relief at rest — can tempt patients and clinicians alike to manage the condition through repeated rest cycles alone. This approach carries a genuine risk: cumulative degenerative change within an inadequately treated tendon can progress to structural failure, and patellar tendon rupture, though not inevitable, is a recognised complication of long-standing or poorly managed tendinopathy. That risk is the reason this condition warrants a structured treatment pathway rather than indefinite watchful waiting.

What conservative care involves and what it can achieve

A well-constructed conservative programme is not simply a list of exercises prescribed at a single appointment. It is a structured, progressive course of treatment delivered over several weeks, with each component serving a defined role.

The clinical foundation is eccentric loading. The Alfredson decline squat protocol — in which the patient performs slow, controlled single-leg squats on a 25-degree decline board, specifically loading the tendon through its painful range — has the strongest evidence base, with randomised controlled trial data showing measurable improvements in both pain (VAS) and function (VISA-P, the Victorian Institute of Sports Assessment – Patella score). VISA-P is the standard outcome measure for patellar tendinopathy; meaningful improvement on this scale, rather than vague symptom relief, is the appropriate benchmark for evaluating whether conservative care has worked.

Extracorporeal shockwave therapy (ESWT) and dry needling are accepted adjuncts rather than standalone treatments. ESWT may reduce pain sensitisation and stimulate local tissue response; dry needling targets myofascial components that can perpetuate load-related pain. Neither replaces the essential stimulus of structured tendon loading, and both are most useful when layered into a programme centred on eccentric exercise.

Load management and activity modification sit alongside the exercise component, not beneath it. Biomechanical assessment — including gait analysis — can identify training errors, lower-limb alignment issues, or movement patterns that are sustaining excessive patellar tendon stress. Correcting these is part of a complete conservative course.

Full benefit from this programme requires adequate time and consistent adherence. What matters at the transition point covered in the next section is whether the programme has genuinely been tested.

Recognising genuine conservative failure

Defining the point at which conservative care has genuinely failed matters because the alternative — escalating too early or too late — carries real cost. Applied too soon, interventional treatment reaches a tendon that would have responded to more time and better loading. Left too late, progressive degeneration narrows the options available.

Most clinical guidelines point to three to six months as the minimum meaningful duration of structured, supervised conservative care before reclassifying disease as chronic recalcitrant patellar tendinopathy. Clinical opinion on the precise threshold varies, and individual clinicians may apply shorter or longer windows depending on disease severity and functional demand — but three months represents a reasonable floor, not a soft suggestion.

Duration alone does not determine failure. Three signals, taken together, constitute a more reliable picture: persistent pain with tendon loading despite programme adherence; no meaningful improvement in VISA-P score across successive assessments; and imaging — ultrasound or MRI — showing ongoing tendon degeneration without structural recovery. Any one of these in isolation is insufficient grounds for escalation.

Before concluding that the tendon has failed to respond, it is worth establishing that the programme itself was adequate. Poor adherence, absence of biomechanical correction, and subtherapeutic loading — too light, too infrequent, or on a gradient that never challenged the tendon — can all produce apparent failure without genuine treatment resistance.

Where entheseal pathology is primarily inflammatory rather than degenerative, the mechanism of conservative failure is distinct, and the escalation pathway that follows differs accordingly — a distinction developed in the sections ahead.

Why corticosteroid injections are the wrong next step

Steroid injection is one of the most commonly expected next steps after physiotherapy — patients frequently arrive having been told, or having assumed, that a corticosteroid injection is the logical progression when exercises have not worked. For most knee conditions, that instinct is reasonable. For recalcitrant patellar tendinopathy, it is not.

The concern is structural, not theoretical. A 2014 systematic review by Dean and colleagues, published in Seminars in Arthritis and Rheumatism, examined the effects of local glucocorticoid on tendon tissue and found that the risks can outweigh the benefits in this context. Local corticosteroid may weaken the collagen architecture of an already compromised tendon — precisely the opposite of what chronic recalcitrant disease requires. Any short-term pain relief the injection produces can, in effect, work against the patient: a tendon that is less painful is more likely to be loaded without appropriate caution, and one that has been structurally weakened by the glucocorticoid is more vulnerable to the cumulative tensile forces that caused the problem in the first place. The result is a masked degenerative process with a higher risk of tendon rupture.

This contraindication is specific to recalcitrant tendinopathy. Corticosteroid injections retain an evidence-based role in other knee conditions — prepatellar bursitis, for example — and should not be dismissed as universally problematic. Context determines the risk calculus.

One clinically important exception concerns enthesitis driven by an underlying inflammatory arthropathy such as psoriatic arthritis or ankylosing spondylitis. Where entheseal inflammation is part of a systemic inflammatory condition, the appropriate route is specialist rheumatological assessment and, where indicated, biologic disease-modifying therapy — not a local corticosteroid injection to the tendon attachment.

PRP and biologic escalation for chronic recalcitrant disease

Platelet-rich plasma (PRP) is currently the best-evidenced interventional option for chronic recalcitrant patellar tendinopathy — not as an experimental adjunct, but as a structured clinical escalation step with prospective series data, a randomised trial, and confirmed durability behind it.

Two prospective series examined a protocol of three ultrasound-guided intratendinous PRP injections — 5 mL each — delivered either one or two weeks apart in patients who had already exhausted conservative management. Both demonstrated significant improvement in symptoms and function alongside high patient satisfaction. One series documented return to pre-symptom sporting level, a practical outcome measure for active patients that sits alongside functional scores rather than replacing them. Four-year follow-up data from one series confirmed that clinical gains held over time rather than attenuating after the initial treatment period.

What distinguishes the evidence further is an MRI finding from one series: objective normalisation of tendon architecture following PRP treatment. This is a structural marker of remodelling — not merely symptom suppression — and is particularly relevant in insertional entheseal disease, where the burden of pathology sits at the inferior patellar pole. Ultrasound guidance is not incidental to the protocol; it ensures the injectate reaches the pathological tissue within the tendon rather than the surrounding soft tissue, and precision of delivery in insertional disease is what separates the evidence-backed approach from less controlled injection techniques.

A randomised controlled trial comparing leukocyte-rich PRP to dry needling further consolidated PRP as the preferred option at this stage of the treatment ladder.

Bone marrow aspirate concentrate (BMAC) is under investigation as a further biologic option in tendon pathology, but patellar-specific evidence remains limited and it should be regarded as investigational at present.

Across orthobiologics as a class, current evidence does not yet support definitive treatment recommendations for every patient — which biologic approach fits an individual's disease pattern and activity demands is a decision best reached through a consultant-led specialist assessment.

When surgery is the answer and what to expect

Surgery represents the final rung on the escalation ladder — reached only when both structured conservative care and appropriate biologic intervention have been exhausted, and when imaging and clinical assessment confirm structural disease that will not resolve without operative attention. It is not a sign that other treatments have failed; it is the correct option for a defined group of patients who have moved through the earlier stages appropriately.

The surgical approaches include arthroscopic or open debridement of degenerative tendon tissue, excision of pathological entheseal tissue at the inferior patellar pole, and inferior pole drilling to stimulate a healing response. The distinction drawn in the previous section between degenerative enthesopathy and inflammatory enthesitis carries particular weight here. Where abnormal, disorganised tendon tissue at the bony attachment is the structural problem, operative debridement addresses it directly. Where inflammation is driven by an underlying systemic condition, disease-modifying treatment is more likely to reach the cause — and surgery less likely to resolve it.

The surgical evidence base for patellar tendinopathy is less extensive than for the biologic tier. Technique selection is guided by expert consensus and case-series data rather than large randomised trials, and this should be communicated clearly to any patient considering this route. Recovery is staged and individually variable; return to sport following patellar pole surgery is typically longer than after PRP, and realistic expectations are best established through a pre-operative consultation rather than inferred from general estimates.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Consultant-led assessment — including imaging review and discussion of the full treatment pathway — is available at Sleaford NG34 and Grantham NG31; book at lincolnshireknee.co.uk.

What the escalation ladder as a whole makes plain is that patellar tendinopathy is not a single problem requiring a single answer. The clinical case for staging care carefully — neither bypassing earlier steps nor persisting with them past their useful limit — holds at every level, from eccentric loading through to operative management, and the evidence at each stage supports that discipline.

1. [1] Patellar tendinitis (Jumper's Knee) — Wikipedia. https://en.wikipedia.org/?curid=2533397 https://en.wikipedia.org/?curid=2533397
2. [2] Enthesopathy — Wikipedia. https://en.wikipedia.org/?curid=2908246 https://en.wikipedia.org/?curid=2908246
3. [3] Tendinopathy — Wikipedia. https://en.wikipedia.org/?curid=244103 https://en.wikipedia.org/?curid=244103